Engineering

Education

Business Development

Administrative

Operations

Legal

Information Technology

Research

Finance

Program and Project Management

Generative AI drug creation for biologic therapeutics

Founder & CEO

Chief Financial Officer & Chief Business Officer

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

Absci plans Phase 2 trial of ABS-201 for endometriosis in mid-2027

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)

AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

Senior/Staff AI Scientist - Target Discovery

Absci is a clinical-stage biotechnology company advancing novel therapeutics using generative AI. The Senior/Staff AI Scientist will develop and deploy protein design and systems biology models for antibody drug discovery, identify novel therapeutic targets, validate computational approaches, collaborate across scientific disciplines, and mentor other scientists and engineers.

Senior/Staff AI Scientist, Target Discovery